TCM
PLRX icon

Tekla Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Tekla Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-35,233
Closed -$681K – 183
2022
Q4 		$681K Buy
+35,233
New +$737K 0.03% 139

Other funds holding PLRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tekla Capital Management's PLRX Position: Q1 2023 in Review

Tekla Capital Management sold out of Pliant Therapeutics (PLRX) in Q1 2023, closing a stake of 35,233 shares — an estimated $681K sold.

Tekla Capital Management first reported a position in PLRX in Q4 2022 and held it in 1 quarter. The position peaked at $681K in Q4 2022. 143 funds tracked by Wall St. Rank hold PLRX as of Q1 2023.

  • Tekla Capital Management reported no remaining Pliant Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Tekla Capital Management sold 35,233 Pliant Therapeutics shares in Q1 2023, an estimated $681K.
  • Tekla Capital Management first reported a position in Pliant Therapeutics in Q4 2022 and held it in 1 quarter.
  • Tekla Capital Management's Pliant Therapeutics position peaked at $681K in Q4 2022.
  • 143 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2023.

Based on Tekla Capital Management's 13F filing for Q1 2023, filed 10 May 2023.